PLATO

Principal Investigator:
Peter Fattal MD (Covenant)

Sub Investigator:
Sarosh Anwar MD
John Collins MD
William Felten MD
Rao Gudipati MD
Alok Maheshwari MD
Gregory Pellizzon MD

Sponsor:
AstraZeneca Pharmaceuticals LP

Study Purpose:
A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) – PLATO

Objective:
This study is being carried out to see if an investigational medicine called AZD6140, is effective in stopping the formation of new blood clots. This study medication may reduce the risk of medical problems such as heart attack or stroke in patients like you. A study medication is a medication that has not been approved by the US Food and Drug Administration (FDA). It is currently only available to patients in this study. In this study, AZD6140 will be compared with clopidogrel (Plavix®).

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back